StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > News

<< Previous

Bullboard Posts

Next >>

Comment by NewToInvesting7on May 05, 2021 8:02am

261 Views

Post# 33130535

RE:News

Glad to see that StageZero has officially announced this, and hopefully we see significant revenues from this over the next few months.

Since the name "Rexall" was never mentioned, it makes me think that it was Ichor that got the deal with Rexall. Not bashing at all, but wanted to point out that Ichor is one of StageZero's partners. Hopefully we see more NRs where other partners deals are announced.

Woud actually like to know more about the agreement between StageZero and Ichor, so that I can understand the potential revenue implications. For example, does StageZero generate $100 per test, while Ichor gets $149, which Ichor then shares with any of its partners (e.g. Rexall)?

Cheers!